|
Mutation Information
|
Mutation Site
|
W172L |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
S |
|
Genotype/Subtype
|
C |
|
Relevant Drug
|
adefovir (ADV) |
|
Country
|
Japan |
Literature Information
|
PubMed PMID
|
18433925
|
|
Disease
|
Chronic hepatitis B
|
|
Published Year
|
2008 |
|
Journal
|
Journal of hepatology |
|
Title
|
Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. |
|
Author
|
Yatsuji H,Suzuki F,Sezaki H,Akuta N,Suzuki Y,Kawamura Y,Hosaka T,Kobayashi M,Saitoh S,Arase Y,Ikeda K,Watahiki S,Iwasaki S,Kobayashi M,Kumada H |
|
Evidence
|
On the other hand, at the end of 3 years of ADV therapy, all rtA181T mutant strains changed to double nucleotide substitutions (TGG to TTA), which induced amino acid substitutions in both polymerase (rtA181T) and HBs antigen (HBs W172L) developed.
|
|
|
HBV Mutation Detail Information